Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Citi Reiterates Buy Rating on Eli Lilly (LLY)
June 25, 2025 5:11 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $1,190.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Given compelling data, Lilly and Novo have reframed obesity as a treatable disease, not just a lifestyle/behavior-based condition. The obesity paradigm should further... More
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.8% Yield
June 23, 2025 11:37 AM EDTEli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $1.50 per share, or $6 annualized.
The dividend will be payable on September 10, 2025, to stockholders of record on August 15, 2025, with an ex-dividend date of August 14, 2025.
The annual yield on the dividend is 0.8... More
Evercore ISI Reiterates In Line Rating on Eli Lilly (LLY)
June 23, 2025 11:18 AM EDTEvercore ISI analyst Umar Raffat reiterated an In Line rating on Eli Lilly (NYSE: LLY)
The analyst commented, "I dont think Street was expecting much on weight loss with bimagrumab (which is not a GLP) and it put up 10% weight loss which surprised me in a very good way. On... More
BMO Capital: 'Eli Lilly (LLY) Metabolic Portfolio Shows New Legs at ADA Event'
June 23, 2025 9:46 AM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $900.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented: "Lilly Metabolic Portfolio Shows New Legs at ADA Event; Lilly, forever one to not rest on its laurels. Full... More
Truist Reiterates Buy Rating on Eli Lilly (LLY) Following OFG Presentation at ADA
June 23, 2025 9:22 AM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,038.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented: "We attended the orforglipron (OFG) presentation at ADA, received feedback on the drug from several KOLs present at the conference and also... More
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
June 23, 2025 7:09 AM EDTCantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $975.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented, Lilly notably (1) emphasized eloralintide is a selective amylin receptor agonist (vs. calcitonin receptor agonist), which it believes should offer an improved GI profile potentially offering... More
GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
June 20, 2025 10:02 AM EDTGLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
... More